The global pharmacogenomics market is witnessing rapid growth as healthcare increasingly embraces personalized medicine. According to market estimates, the market is projected to grow from USD 3.5 billion in 2023 to USD 5.8 billion by 2028, registering a CAGR of 10.6% during the forecast period.
Pharmacogenomics combines genomics with pharmacology to understand how an individual’s genetic profile influences drug response. This approach enables healthcare providers to prescribe the most effective medications while minimizing adverse drug reactions, making it a cornerstone of precision medicine.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251
What Is Pharmacogenomics?
Pharmacogenomics is the study of how genetic variations affect an individual’s response to medications. By analyzing a patient’s DNA, clinicians can identify genetic markers that predict drug efficacy, toxicity, or dosage requirements.
Applications of pharmacogenomics include:
- Personalized drug selection
- Precision oncology
- Rare disease diagnosis
- Cardiovascular medicine
- Neurology
- Psychiatry
- Infectious disease management
- Clinical drug development
The growing use of next-generation sequencing (NGS), companion diagnostics, and genomic testing is accelerating the adoption of pharmacogenomics across research and clinical settings.
Key Factors Driving Market Growth
Rising Genomics Research Activities
Governments, research institutes, and biotechnology companies are investing heavily in genomic research to better understand disease biology and identify new therapeutic targets. These initiatives continue expanding the application of pharmacogenomics in healthcare.
Increasing Burden of Chronic and Genetic Diseases
The growing prevalence of cancer, cardiovascular disorders, neurological diseases, diabetes, and rare genetic disorders is creating strong demand for precision medicine solutions. Pharmacogenomics enables clinicians to tailor therapies based on genetic profiles, improving treatment outcomes.
Growing Investments and Funding
Public and private organizations are increasing investments in genomic infrastructure, sequencing technologies, and precision medicine initiatives. Funding for national genome programs and large-scale clinical research projects is supporting market expansion.
Advances in Next-Generation Sequencing
The declining cost and increasing speed of next-generation sequencing have made comprehensive genetic testing more accessible. High-throughput sequencing platforms now enable faster identification of clinically relevant genetic variants, supporting broader adoption of pharmacogenomic testing.
Expansion of Precision Medicine
Healthcare providers are increasingly integrating pharmacogenomic testing into routine clinical practice to reduce adverse drug reactions and improve therapeutic effectiveness. This trend is expected to significantly boost market demand over the coming years.
Request Sample Pages: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142682251
Emerging Trends Shaping the Market
Several technological and clinical trends are transforming the pharmacogenomics landscape, including:
- AI-driven genomic data interpretation
- Multi-gene pharmacogenomic panels
- Companion diagnostics for targeted therapies
- Whole-genome and whole-exome sequencing
- Cloud-based genomic analytics
- Integration of pharmacogenomics into electronic health records
- Increased adoption of liquid biopsy technologies
These innovations are making personalized medicine more practical, scalable, and clinically valuable.
Competitive Landscape
The pharmacogenomics market remains highly competitive, with global life science companies focusing on innovation, strategic partnerships, acquisitions, and geographic expansion.
Major companies operating in the market include:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
These organizations continue expanding their genomic technology portfolios while supporting precision medicine initiatives worldwide.
Illumina Strengthens Leadership Through Strategic Collaborations
Illumina remains a leading provider of sequencing and array-based genomic technologies used in research and clinical diagnostics.
Its product portfolio includes:
- Next-generation sequencing platforms
- Microarray systems
- Sequencing consumables
- Genomic analysis software
- Clinical genomic solutions
A significant milestone came in March 2023, when Illumina and Myriad Genetics expanded their strategic collaboration to improve access to TruSight Oncology 500 HRD testing in the United States. The alliance supports companion diagnostics and advances gene-targeted cancer therapies, strengthening Illumina’s position in precision oncology.
Thermo Fisher Scientific Expands Global Access to Genomic Testing
Thermo Fisher Scientific continues to play a major role in advancing pharmacogenomics through its broad portfolio of laboratory instruments, reagents, software, sequencing technologies, and diagnostic solutions.
The company has actively pursued growth through acquisitions, partnerships, and collaborations.
In May 2023, Thermo Fisher partnered with Pfizer to expand access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients across more than 30 countries in Latin America, Africa, the Middle East, and Asia. The initiative aims to improve access to genomic testing and enable healthcare providers to deliver more personalized cancer treatments.
Danaher Expands Its NGS Portfolio
Danaher Corporation continues strengthening its presence in pharmacogenomics through strategic acquisitions and innovation in molecular biology technologies.
The company’s genomic capabilities have expanded through acquisitions, including:
- DNA Integrated Technologies (2018)
- Archer NGS research assays acquired by Integrated DNA Technologies (IDT) from Invitae Corporation in April 2023
This acquisition broadened IDT’s xGen NGS portfolio, providing researchers with advanced tools for detecting cancer biomarkers and gene fusions, supporting precision oncology research and drug development.
Opportunities for Future Growth
The pharmacogenomics market offers substantial opportunities as personalized healthcare becomes more widely adopted. Key growth areas include:
- Precision oncology
- Companion diagnostics
- Population-scale genomic screening
- Pharmacogenomic testing in primary care
- AI-enabled genomic interpretation
- Rare disease diagnostics
- Personalized drug development
- Clinical decision support systems
Increasing collaboration between pharmaceutical companies, diagnostic manufacturers, healthcare providers, and research institutions will further accelerate market expansion.
Future Outlook
Pharmacogenomics is expected to become an integral part of routine healthcare as clinicians increasingly rely on genetic information to guide treatment decisions. Advances in sequencing technologies, bioinformatics, artificial intelligence, and companion diagnostics are making personalized medicine more accessible and cost-effective.
As investments in genomics continue to rise and healthcare systems prioritize precision medicine, the pharmacogenomics market is well positioned for sustained growth. Companies that focus on innovation, strategic collaborations, and expanding access to genomic testing will play a pivotal role in shaping the future of personalized healthcare and improving patient outcomes worldwide.